NGI226

DRUG2 trials

Sponsors

Novartis Pharma AG, Novartis Pharmaceuticals

Conditions

Achilles Tendinopathy

Phase 2

A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy

CompletedNCT05592990

Novartis PharmaceuticalsAchilles Tendinopathy

Start: 2023-06-14End: 2026-02-03Updated: 2026-09-09

A two part, randomized, participant and investigator-blinded, 2-arm, parallel-design, placebo-controlled study to evaluate the safety, tolerability and preliminary efficacy of NGI226 microparticles on tendon regeneration in patients with Achilles tendinopathy

RecruitingCTIS2022-500863-10-00

Novartis Pharma AGAchilles Tendinopathy

Start: 2023-10-18Target: 26Updated: 2025-06-30